GB2507254A - Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof - Google Patents

Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof Download PDF

Info

Publication number
GB2507254A
GB2507254A GB1216396.0A GB201216396A GB2507254A GB 2507254 A GB2507254 A GB 2507254A GB 201216396 A GB201216396 A GB 201216396A GB 2507254 A GB2507254 A GB 2507254A
Authority
GB
United Kingdom
Prior art keywords
weight
cinnamon
fenugreek
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1216396.0A
Other versions
GB201216396D0 (en
Inventor
Ajit Ramanial Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB1216396.0A priority Critical patent/GB2507254A/en
Publication of GB201216396D0 publication Critical patent/GB201216396D0/en
Publication of GB2507254A publication Critical patent/GB2507254A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A composition for oral ingestion comprises or consists white kidney bean extract, fenugreek, cinnamon and a chromium(III) compound. The composition finds use in inhibiting the breakdown of carbohydrates passing through the gastrointestinal tract and thereby preventing or reducing absorption of sugar. The composition is suitable for helping regulate blood glucose levels, the dosing of which can be conveniently controlled without medical supervision. Also disclosed are capsules and medical devices containing the aforementioned composition.

Description

A COMPOSITION FOR REDUCING THE CONSUMPTION OF FOOD AND THE
ABSORPTION OF ITS CARBOHYDRATE CONSTITUENTS
This invention relates to a composition for use in inhibiting the breakdown of carbohydrates passing through the gastrointestinal tract and thereby preventing or reducing absorption of sugar.
Background of the invention
Regulation of sugar intake is important for maintaining health and wellbeing. If the level of sugar intake is highly variable the subject can experience periods of hypoglycaemia and hyperglycaemia, which has an adverse effect on energy levels and cognitive function. Persistent high intake of sugar can cause obesity and in some cases type 2 diabetes.
Obesity can be treated in pad by reducing the intake of food. Various specialised diets have been developed including low-carbohydrate diets, and low-fat diets.
However, successful application of these diets requires strong will power, and careful dietary management using specialist knowledge of nutritional content of food or assistance from third party experts. As a result, diets often fail.
Diabetes is characterised by an inability for the body to properly regulate blood glucose levels. It is caused by a lack of insulin secretion (type 1 diabetes) or a diminished cellular response to insulin (insulin resistance; type 2 diabetes). As a result, diabetics require medical treatment to assist with blood glucose regulation and can suffer a wide range of medical complications such as neuropathy and vascular disease which can lead to, for example, blindness and the requirement for limb amputation. It is therefore important to limit the intake of sugar to avoid the development of type 2 diabetes.
However, even with low-sugar diets, dietary complex carbohydrates are digested to form sugars. For example, amylase digests starch in the gastro-intestinal (GI) tract to form glucose, which is directly absorbed into the bloodstream in the intestine. Thus, subjects must also reduce complex carbohydrate intake to reduce sugar intake. This is undesirable because it requires the regulation of intake of many basic foodstuffs, for example, bread, rice and pasta.
I
There is therefore a need to reduce sugar intake without the difficulties associated with a managing a low-carbohydrate diet.
Formulations comprising an amylase inhibitor have been proposed to inhibit the digestion of carbohydrates and so reduce glucose absorption. White kidney beans, as well as some other varieties of the common bean (Phaseolus vulgaris), are a source of a proteinaceous aipha-amylase inhibitor called phaseolomin.
Cinnamon is a spice obtained from the inner bark of trees from the genus Cinnamomum. It is widely used as a culinary spice for its distinctive flavour.
Cinnamon has also been used in folk and traditional medicine to treat a variety of conditions. A recent report has indicated that cinnamon may reduce blood glucose and cholesterol in subjects with type 2 diabetes (Khan et al, 2003, Diabetes Care 26(12):3215-8).
EP 1609466 relates to essential oil formulations relating to a method for blocking the irreversible inactivation of vanilloids, comprising numerous purified natural products including from white kidney beans. However, manufacture of this formulation is complex due to the purification steps involved in obtaining the protein fractions of kidney bean or purified alpha-amylase.
KR 1020050120302 relates to formulations comprising purified natural extracts including white kidney bean extract. EP 1732397 relates to formulations comprising a purified extract from phytohemagglutinin-essentially free beans containing an alpha-amylase inhibitor. However, as with EP 1609466, manufacture of these formulations is complex due to the purification steps involved, and the beans used are not kidney beans, which contain phytohemagglutinin.
EP 1295535 and EP 1618801 relate to formulations comprising phaseolamin and a sophisticated glycoprotein matrix into which a mineral such as chromium is incorporated.
Thus, at present, there are numerous formulations comprise white kidney bean extract. However, there is a need for an alternative or improved nutritional supplement that provides a more targeted range of micronutrients that help regulate blood glucose levels, the dosing of which can be conveniently controlled without medical supervision, and which is less complex to manufacture.
Summary of the invention
The present invention provides an alternative or improved composition for regulating blood glucose in the absence of medical supervision.
Accordingly, in a first aspect, the invention provides a composition for oral ingestion comprising white kidney bean extract, fenugreek, cinnamon and a chromium compound.
The invention provides a composition that advantageously includes several components that work in tandem to reduce glucose absorption.
The chromium is in the form of a chromium compound, preferably a chromium (Ill) compound such as a chromium (Ill) salt or coordination complex, more preferably preferably chromium (Ill) picolinate. Chromium (Ill) picolinate may be prepared by aqueous reaction of chromium (Ill) chloride with three equivalents of picolinic acid, and is commercially available from Intatrade Chemicals GmbH, Germany. In the context of the present invention, the chromium compound (e.g. chromium (Ill) picolinate) is believed to control cholesterol levels and decrease cravings for food in general (including carbohydrates) and in particular fat.
The combination of cinnamon and the chromium compound advantageously also reduce the levels of intake and blood levels of lipids.
Fenugreek is derived from plants of the tamily Fabaceac. Its seeds are widely used as a culinary spice and its leaves and shoots are used mainly as a herb.
Fenugreek is said to have medical uses in the treatment of menopausal symptoms, loss of appetite and skin conditions and to stimulate milk production in breastfeeding women. A few studies indicate that fenugreek may help lower blood glucose levels in diabetics.
Preferably the fenugreek comprises or consists of fenugreek seed material, for example comminuted or ground fenugreek seeds.
An extract of white kidney beans containing concentrated phaseolomin may be produced by a method as described in: Celleno L, Tolaini M, D'Amore A. Perricone N, Preuss H (2007). "A Dietary Supplement Containing Standardized Phaseolus vulgaris Extract Influences Body Composition of Overweight Men and Women". International Journal of Medical Sciences 4: 45-52; Joe A. Vinson, Ph.D., and Donna M. Shuta, B.S.. Investigation of an Amylase Inhibitor on Human Glucose Absorption After Starch Consumption; Jay Udani, MD, Medical Director, Integrative Medicine Program, Northridge Hospital Medical Center, Northridge, CA; Betsy Singh, Ph.D.! Dean of Research, Southern California University of Health Sciences (2007). "Blocking Carbohydrate Absorption and Weight Loss: A Clinical Trial Using a Proprietary Fractionated White Bean Extract". Alternative Therapies in Health and Medicine 13 (4): 32-7.
PMID 17658120; and Jay Udani, MD, Mary Hardy, MD, and Damian C. Madsen. "Blocking Carbohydrate Absorption and Weight Loss: A Clinical Trial Using Phase 2 Brand Proprietary Fractionated Bean Extract". Alternative Medicine Review 9 (2); The term cinnamon' as used herein refers to the inner bark of tress of the genus Cinnamomum, and in particular to a coniminuted form of the bark.
The composition may contain from 50 to 95 % by weight of white kidney bean extract, from 5 to 40 % by weight of fenugreek, from 5 to 30 % by weight of cinnamon and from 0.0005 to 0.02 % by weight of achromium compound.
More particularly, the composition may contain from 75 to 85 % by weight of white kidney bean extract, from 5 to 15% by weight of fenugreek, from 5 to 10 % by weight of cinnamon and from 0.001 to 0.01 % by weight of achromium compound.
The composition may contain from 2 to 50 parts by weight of white kidney bean extract, from 0.2 to 10 parts by weight of fenugreek, from 0.2 to 10 parts by weight of cinnamon and from 0.0001 to 0.001 parts by weight of a chromium compound.
More particularly, the composition may contain from 0.4 g to 1.5 g of the white kidney bean extract. from 25 mg to 200 mg of the fenugreek, from 30 mg to mg of the cinnamon and from 15 pg to 60 pg of the chromium compound.
For example, the composition may contain from 0.6 g to 1 g of the white kidney bean extract, from 50mg to 150mg of the fenugreek, from 60 mgto 100mg of the cinnamon and from 30 pg to 50 pg of the chromium compound.
In an embodiment of the invention, the composition may contain approximately 0.8 g of the white kidney bean extract, approximately 100 mg of the fenugreek, approximately 75 mg of the cinnamon and approximately 40 pg of the chromium compound.
For the avoidance of doubt, the reference to the amount of chromium compound refers to the amount of chromium per se in the compound.
In an embodiment of the invention, the composition consists or consists essentially of white kidney bean extract, fenugreek, cinnamon and a chromium compound, optionally with pharmaceutically acceptable excipients.
By consists essentially' it is meant that the compositions contain the recited components with less than 5 pg, preferably 1 pg of other components.
The components (and the concentrations thereof) of the compositions of the invention are preferably selected such that there is a synergistic reduction in blood glucose levels.
The compositions of the invention may be presented in the form of capsules.
The compositions of the invention may also be presented as medical devices, the term medical device as used herein referring to a substance which whilst providing a medical benefit to a subject, is not absorbed significantly from the subject's GI tract and does not exert its actions by pharmacological means.
The composition, capsule or medical device of the invention as defined herein may be used in inhibiting the breakdown of carbohydrates passing through the gastrointestinal tract and thereby preventing or reducing absorption of sugar.
The compositions of the invention may advantageously be beneficial to subjects suffering from diabetes.
An aspect of the invention provides a method of inhibiting the breakdown of carbohydrates passing through the gastrointestinal tract and thereby preventing or reducing absorption of sugar, which comprises administration of a composition! capsule or medical device according to the invention.
The white bean extract may be presented in the form of a liquid extract, for example an oleoresin, or a powder, preferably a powder. The white bean extract may be presented in powder form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) of 600 pM or less. Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less.
Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% by weight of the particles have a particle size (e.g. diameter) of 210 pM or less. Such particles will pass through a 70 mesh sieve. In another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
The cinnamon may be presented in comminuted form, for example in the form of a powder such as that produced by grinding cinnamon inner bark. The powdered cinnamon may be presented in form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) of 600 pM or less.
Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less. Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% by weight of the particles have a particle size (e.g. diameter) of 210 pM or less. Such particles will pass through a 70 mesh sieve. In another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
The fenugreek may be presented in comminuted form, for example in the form of a powder such as that produced by grinding fenugreek seeds. The powdered fenugreek may be presented in form wherein at least 99.5% by weight of the particles forming the powder have a particle size (e.g. diameter) 01600 pM or less.
Such particles will pass through a 30 mesh sieve. In one embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 400 pM or less. Such particles will pass through a 40 mesh sieve. In another embodiment, at least 99.5% by weight of the particles have a particle size (e.g. diameter) of 300 pM or less. Such particles will pass through a 50 mesh sieve. In a further embodiment, at least 95% by weight of the particles have a particle size (e.g. diameter) of 210 pM or less. Such particles will pass through a 70 mesh sieve. In another embodiment, at least 75% by weight of the particles will pass through a 50 to 60 mesh sieve and have particle sizes in the range from 230 to 280 pM.
In the compositions of the present invention, the chromium compound may be presented in powder form.
The compositions of the invention are typically administered with or without meals, preferably before meals, one or more times per day. For example, the compositions may be administered from one to four times per day.
The compositions may be administered so that the daily intakes of the components areasfollows: White kidney bean extract: 0.2 g to 20 g Fenugreek: 20 mg to 2 g Cinnamon: 20 mg to 2 g Chromium compound: 6 pg to 0.6 mg The compositions of the invention reduce the amount of breakdown of carbohydrates in the GI tract, thereby reducing the amount of sugar available for absorption. This in turn helps regulate the blood glucose levels by reducing saturation of the body's natural glucose regulatory system. This is believed to be particularly important for subjects with a diminished glucose regulatory system such as diabetics.
The compositions of the invention also reduce the intake and blood levels of lipids, in particular cholesterol. This is also believed to be particularly important for subjects with diabetes because diabetics tend to have increased levels of blood lipid levels, thereby that increasing the risk of heart disease and stroke.
S
The invention will now be illustrated, but not limited, by reference to the following
specific example.
EXAMPLE 1
Caøsule formulation 1 Two part capsule shells formed from hydroxypropyl methylcellulose are filled with a mixture of white kidney bean extract, fenugreek, cinnamon and chromium picolinate in the following amounts per capsule: White kidney bean extract: 800 mg Fenugreek: 100mg Cinnamon: 75 mg Chromium: 40 pg (present as chromium picolinate) Two to four capsules per day are taken as a food supplement before meals.
It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above without departing from the principles underlying the invention. All such modifications and alterations are intended to be embraced by this application.

Claims (18)

  1. CLAIMS1. A composition for oral ingestion comprising white kidney bean extract, fenugreek, cinnamon and a chromium compound.
  2. 2. A composition according to claim 1 comprising from 50 to 95 % by weight of white kidney bean extract, from 5 to 40 % by weight of fenugreek, from 5 to % by weight of cinnamon and from 0.0005 to 0.02 % by weight of a chromium compound.
  3. 3. A composition according to claim 2 comprising from 75 to 85 % by weight of white kidney bean extract! from Sto 15% by weight of fenugreek, from 5 to 10 % by weight of cinnamon and from 0.001 to 0.01 % by weight of a chromium compound.
  4. 4. A composition according to claim 1 comprising from 2 to 50 parts by weight of white kidney bean extract, from 0.2 to 10 parts by weight of fenugreek, from 0.2 to 10 parts by weight of cinnamon and from 0.0001 to 0.001 pads by weight of a chromium compound.
  5. 5. A composition according to claim 4 comprising from 0.4 g to 1.5 g of the white kidney bean extract, from 25 mg to 200 mg of the fenugreek, from 30 mgto 150mg of the cinnamon and from 15 pg to 60 pg of the chromium compound.
  6. 6. A composition according to claim 5 comprising from 0.6 g to 1 g of the white kidney bean extract, from 50 mg to 150 mg of the fenugreek, from 60 mg to 100mg of the cinnamon and from 30 pgto 50 pg of the chromium compound.
  7. 7. A composition according to claim 6 containing approximately 0.8 g of the white kidney bean extract, approximately 100mg ofthefenugreek, approximately 75 mg of the cinnamon and approximately 40 pg of the chromium compound.
  8. 8. A composition according to any one of claims 1 to 7 wherein the white kidney bean extract is presented in the form of a powder in which at least 75% by weight of the particles have particle sizes in the range from 230 to 280 pM.
  9. 9. A composition according to any one of claims 1 to 8 wherein the fenugreek is presented in the form of a powder in which at least 75% by weight of the particles have particle sizes in the range from 230 to 280 pM.
  10. 10. A composition according to any one of claims 1 to 9 wherein the cinnamon is presented in the form of a powder in which at least 75% by weight of the particles have particle sizes in the range from 230 to 280 pM.
  11. 11. A composition according to any one of claims 1 to 10 wherein the chromium compound is presented in the form of a powder.
  12. 12. A composition according to any one of claims 1 to 11 wherein the chromium compound is chromium (Ill) picolinate.
  13. 13. A composition according to any of claims ito 12 containing 0.8 g of the white kidney bean extract, 100 mg of the fenugreek, 75 mg of the cinnamon and 40 pg of the chromium (Ill) picolinate.
  14. 14. A composition according to any previous claim consisting of white kidney bean extract, fenugreek, cinnamon and a chromium compound.
  15. 15. A capsule containing a composition according to any one of claims 1 to 14.
  16. 16. A medical device comprising a composition according to any one of claims ltol4.
  17. 17. A composition, capsule or medical device according to any one of claims 1 to 16 for use in inhibiting the breakdown of carbohydrates passing through the gastrointestinal tract and thereby preventing or reducing absorption of sugar.
  18. 18. A method of inhibiting the breakdown of carbohydrates passing through the gastrointestinal tract and thereby preventing or reducing absorption of sugar, which comprises administration of a composition, capsule or medical device according to any one of claims 1 to 16.
GB1216396.0A 2012-09-13 2012-09-13 Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof Withdrawn GB2507254A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1216396.0A GB2507254A (en) 2012-09-13 2012-09-13 Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1216396.0A GB2507254A (en) 2012-09-13 2012-09-13 Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof

Publications (2)

Publication Number Publication Date
GB201216396D0 GB201216396D0 (en) 2012-10-31
GB2507254A true GB2507254A (en) 2014-04-30

Family

ID=47144255

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1216396.0A Withdrawn GB2507254A (en) 2012-09-13 2012-09-13 Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof

Country Status (1)

Country Link
GB (1) GB2507254A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031425A1 (en) * 2016-08-08 2018-02-15 Glucare, Llc Pharmaceutical compositions comprising chromium and carbohydrate blockers
CN108272073A (en) * 2017-12-29 2018-07-13 广州赢特保健食品有限公司 A kind of weight losing meal-replacing powder and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112568431A (en) * 2020-12-03 2021-03-30 山东腾贵医药有限公司 Pre-meal dusting composition for inhibiting starch absorption and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295535A2 (en) * 2001-09-25 2003-03-26 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US20050208161A1 (en) * 2002-11-07 2005-09-22 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
US20050238638A1 (en) * 2004-04-21 2005-10-27 Jonathan Gutwein Dietary Supplement that Serves as a Carbohydrate Blocker and Hangover Remedy
US20090004306A1 (en) * 2007-06-26 2009-01-01 Heather Renee Pridemore Composition for treatment of diabetes and maintaining healthy blood glucose levels
US20090042779A1 (en) * 2004-03-30 2009-02-12 Roberto Bollini Purified Extract of an Alpha-Amylase Inhibitor From Phytoemagglutinin-Essentially Free Beans, Process for Its Extraction and Compositions Containing It
US20090263505A1 (en) * 2008-04-21 2009-10-22 George Roderick Hammons Dietary therapeutic compositions for ameliorating disease symptoms and conditions associated with diabetes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295535A2 (en) * 2001-09-25 2003-03-26 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US20050208161A1 (en) * 2002-11-07 2005-09-22 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
US20090042779A1 (en) * 2004-03-30 2009-02-12 Roberto Bollini Purified Extract of an Alpha-Amylase Inhibitor From Phytoemagglutinin-Essentially Free Beans, Process for Its Extraction and Compositions Containing It
US20050238638A1 (en) * 2004-04-21 2005-10-27 Jonathan Gutwein Dietary Supplement that Serves as a Carbohydrate Blocker and Hangover Remedy
US20090004306A1 (en) * 2007-06-26 2009-01-01 Heather Renee Pridemore Composition for treatment of diabetes and maintaining healthy blood glucose levels
US20090263505A1 (en) * 2008-04-21 2009-10-22 George Roderick Hammons Dietary therapeutic compositions for ameliorating disease symptoms and conditions associated with diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
http://www.ironmaxx.de/products/en/Sports-Nutrition-A-Z/Lipometabolism/Dietbooster-150-Capsules.html 01/05/2012 *
http://www.ynpstore.com/supplements/ARG/SugarBalance 27/05/2012 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031425A1 (en) * 2016-08-08 2018-02-15 Glucare, Llc Pharmaceutical compositions comprising chromium and carbohydrate blockers
CN108272073A (en) * 2017-12-29 2018-07-13 广州赢特保健食品有限公司 A kind of weight losing meal-replacing powder and preparation method thereof

Also Published As

Publication number Publication date
GB201216396D0 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
CN103238897B (en) Composite plant solid drink suitable for diabetic patients
CN103099089B (en) Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof
CN102919836B (en) Health-care product capable of reducing blood glucose, releasing pressure, reducing lipid, relaxing bowel, beautifying, losing weight and resisting fatigue and production process thereof
CN107319525A (en) One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof
CN106858620A (en) A kind of anaemia tailored version clinical nutrition formula and preparation method thereof
CN106174585A (en) Hypoglycemic compositions and hypoglycemic compound probiotic spy's dietary seafood
Bumrungpert et al. Effects of fenugreek, ginger, and turmeric supplementation on human milk volume and nutrient content in breastfeeding mothers: A randomized double-blind controlled trial
CN107080265A (en) Suitable for the strange sub- seed dietary fiber meal replacement powder of diabetes
JP2007535576A (en) Nutritional composition that promotes rapid weight loss, burns calories, increases heat generation, assists in energy metabolism and / or suppresses appetite
AU2019285716A1 (en) Intact pea protein-based nutrient composition
CN107072276A (en) A kind of nutraceutical of optimization
CN107373672A (en) A kind of irregular menstruation women tailored version clinical nutrition formula and preparation method thereof
JP6463504B2 (en) Health supplements for hair growth promotion, hair loss relief and improvement, blood sugar control, gastrointestinal symptom relief and improvement
WO2020039277A1 (en) Enteral or oral nutritional composition
GB2507254A (en) Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof
Lawal et al. Ethnobotanical survey and nutritional composition of medicinal plants used for traditional galactagogue practice in Katsina state, Nigeria
Awulachew The role of wheat in human nutrition and its medicinal value
CN105101817B (en) Edible composition and preparation method thereof and the food comprising said composition
CN102552562A (en) Formula for health care medicine capable of enhancing immunity and delaying aging
Singhal et al. Multifunctional role of green blood therapy to cure for many diseases
US20180169071A1 (en) Nutritional supplement composition
CN103798596B (en) Total nutrient formula food suitable for patients with cardiovascular and cerebrovascular diseases
CN103169125B (en) A kind of nutrition type beverage and preparation method thereof
Lade et al. Benefits of Using Black Garlic and its Role In Treating Liver Diseases Along With Boosting Immunity
Tufail et al. Garden cress seeds: a review on nutritional composition, therapeutic potential, and industrial utilization

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)